Related Experiment Video

Updated: Apr 9, 2026

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

6.3K

Condurango 30C Induces Epigenetic Modification of Lung Cancer-specific Tumour Suppressor Genes via Demethylation

Anisur R Khuda-Bukhsh1, Sourav Sikdar

  • 1Department of Zoology, University of Kalyani, Kalyani, India.

Forschende Komplementarmedizin (2006)
|June 20, 2015
PubMed
Abstract

Insights

Ultra-highly diluted Condurango 30C demonstrated potential in modulating DNA hypermethylation in lung cancer. This epigenetic modification was observed through its effect on tumor suppressor genes, suggesting a novel therapeutic avenue.

Area of Science:

  • Epigenetics
  • Molecular Oncology
  • Pharmacology

Background:

  • DNA hypermethylation is a key driver of cancer progression, leading to the inactivation of tumor suppressor genes.
  • Lung cancer development is associated with aberrant DNA methylation patterns in critical genes.
  • Understanding the epigenetic landscape of lung cancer is crucial for developing novel therapeutic strategies.

Purpose of the Study:

  • To investigate the DNA hypermethylation status in lung cancer.
  • To evaluate the ability of ultra-highly diluted Condurango 30C to modulate DNA methylation in lung cancer.
  • To analyze the effect of Condurango 30C on lung cancer-specific tumor suppressor genes (p15, p16, p53) compared to a placebo.

Main Methods:

  • DNA methylation status was determined using PCR-SSCP analysis on lung cancer-specific tumor suppressor genes (p15, p16, p53).
  • Experiments were conducted using H460-NSCLC cell lines and Bap-induced lung cancer in rats.
  • The effect of Condurango 30C was assessed in a blinded, placebo-controlled manner.

Main Results:

  • Condurango 30C treatment led to a significant decrease in the band intensity of p15 and p53 genes, particularly in their methylated forms in vitro.
  • SSCP analysis indicated that Condurango 30C can reduce DNA methylation in p15 and p53 genes.
  • In vivo, Condurango 30C treatment inhibited p15 hypermethylation in rats with lung cancer.

Conclusions:

  • Condurango 30C exhibits the potential to induce epigenetic modifications in lung cancer.
  • The observed effects are mediated through the modulation of DNA hypermethylation.
  • These findings suggest Condurango 30C as a potential agent for epigenetic therapy in lung cancer.

More Related Videos

Immunostaining for DNA Modifications: Computational Analysis of Confocal Images09:42

Immunostaining for DNA Modifications: Computational Analysis of Confocal Images

Published on: September 7, 2017

10.4K
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

3.3K

Related Concept Videos

Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
4.2K
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
34.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.2K